Download PDF
Thromb Haemost 1997; 78(04): 1193-1201
DOI: 10.1055/s-0038-1657714
Rapid Communication
Schattauer GmbH Stuttgart

Ultrasensitive Fluorogenic Substrates for Serine Proteases[*]

Saulius Butenas
The Department of Biochemistry, Health Science Complex, University of Vermont, Burlington, VT, USA
,
Maria E DiLorenzo
The Department of Biochemistry, Health Science Complex, University of Vermont, Burlington, VT, USA
,
Kenneth G Mann
The Department of Biochemistry, Health Science Complex, University of Vermont, Burlington, VT, USA
› Author Affiliations
Further Information

Publication History

Received 28 1997

Accepted after resubmission 13 June 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Selective, sensitive assays for the quantitation of serine proteases involved in coagulation and fibrinolysis have been developed employing fluorogenic substrates containing a 6-amino-1-naphthalenesulfonamide leaving group (PNS-substrates). Over one hundred substrates were evaluated for hydrolysis by the serine proteases of blood coagulation and fibrinolysis, and substrate structure-efficiency correlations were examined. PNS-substrates which contain Lys in the P1 position are specific for Lys-plasmin and are either not hydrolyzed or hydrolyzed at a relatively low rate by factor Xa, thrombin, or urokinase-type plasminogen activator (uPA). These substrates allow quantitation of Lys-plasmin at concentrations as low as 1 pM. Eighteen of over 90 substrates tested for factor XIa are hydrolyzed by this enzyme at a relatively high rate reaching a kcat value of 170 s-1 and allowing quantitation of factor XIa at 10 fM. Eighteen of almost 90 PNS-substrates tested display high specificity for thrombin, some exceeding that for factor Xa by > 10,000-fold and > 100-fold for activated protein C (APC). Seven of these substrates have a over 100 s-1 and three of them have a KM below 1 μM. They allow the quantitation of thrombin at concentrations as low as 20 fM. For APC, uPA and the factor Vila/tissue factor complex, quantitation is feasible at 1 pM concentration. For factor Xa and factor VIIa the limits are 0.4 pM and 40 pM respectively. The PNS-substrates presented in this study may be employed for the development of direct and sensitive serine protease assays.

This work was supported by Grant from the National Institute of Health HL46703


 

  • References

  • 1 Colman RW, Hirsh J, Marder VC, Salzman EW. Hemostatis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: J. B. Lippincott Company; 1994
    Google Scholar
  • 2 Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 1984; 74: 2033-2041
    CrossrefPubMedGoogle Scholar
  • 3 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744
    PubMedGoogle Scholar
  • 4 McRae BJ, Kurachi K, Heimark RL, Fujikawa K, Davie EW, Powers JC. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor Xlla, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates. Biochemistry 1981; 20: 7196-7206
    CrossrefPubMedGoogle Scholar
  • 5 Cho K, Tanaka T, Cook RR, Kisiel W, Fujikawa K, Kurachi K, Powers JC. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates. Biochemistry 1984; 23: 644-650
    CrossrefPubMedGoogle Scholar
  • 6 Krishnaswamy S. The interaction of human factor Vila with tissue factor. J Biol Chem 1992; 267: 23696-23706
    PubMedGoogle Scholar
  • 7 Shigematsu Y, Miyata T, Higashi S, Miki T, Sadler JE, Iwanga S. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor Vila. J Biol Chem 1992; 267: 21329-21337
    PubMedGoogle Scholar
  • 8 Butenas S, Ribarik N, Mann KG. Syanthatic substrates for human factor Vila and factor VHa-tissue factor. Biochemistry 1993; 32: 6531-6538
    CrossrefPubMedGoogle Scholar
  • 9 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin II. An empirical study. J Biol Chem 1994; 269: 23357-23366
    PubMedGoogle Scholar
  • 10 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin II. A mathematical simulation. J Biol Chem 1994; 269: 23367-23373
    PubMedGoogle Scholar
  • 11 Rand MD, Lock JB, Van’t VeerC, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445
    CrossrefPubMedGoogle Scholar
  • 12 Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 1981; 256: 253-259
    PubMedGoogle Scholar
  • 13 Bachmann F, Kruithof EKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984; 10: 06-17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase- type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemost 1986; 56: 411-414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Lawson JH, Mann KG. Cooparative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 11317-11327
    PubMedGoogle Scholar
  • 16 Astrup T, Mullertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
    CrossrefPubMedGoogle Scholar
  • 17 Kesner A, Troll W. Fluorometric microassay of plasminogen activators. Arch Biochem Biophys 1976; 176: 411-416
    CrossrefPubMedGoogle Scholar
  • 18 Seligsohn U, Østerud B, Rapaport SI. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VH. Blood 1978; 52: 978-988
    PubMedGoogle Scholar
  • 19 Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF-VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991; 66: 529-533
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Radcliffe R, Nemerson Y. Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa. J Biol Chem 1976; 251: 4797-802
    PubMedGoogle Scholar
  • 21 Barlow GH, Francis CW, Marder VJ. On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res 1981; 23: 54-61
    PubMedGoogle Scholar
  • 22 Gyzander E, Eriksson E, Teger-Nilsson AC. A sensitive assay for tissue plasminogen activator activity in plasma using adsorption on lysine-Sepha- rose. Thromb Res 1984; 35: 547-558
    CrossrefPubMedGoogle Scholar
  • 23 Verheijen JH, de JongYF, Chang GTG. Quantitative analysis of mixtures of one-chain and two-chain tissue-type plasminogen activator with a spectrophotometric method. Thromb Res 1985; 39: 281-288
    CrossrefPubMedGoogle Scholar
  • 24 Rao LVM, Rapaport SI. The effect of platelets upon factor Xa-catalyzed activation of factor VH in vitro. Blood 1988; 72: 396-401
    PubMedGoogle Scholar
  • 25 Schechter I, Berger A. On the size of the active site in proteases.I. Papain. Biochem Biophys Res Com 1967; 27: 157-162
    CrossrefPubMedGoogle Scholar
  • 26 Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol 1981; 80: 341-361
    PubMedGoogle Scholar
  • 27 Butenas S, Orfeo T, Lawson JH, Mann KG. Aminonaphthalenesulfona-mides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes. Biochemistry 1992; 31: 5399-5411
    CrossrefPubMedGoogle Scholar
  • 28 Claeson G, Aurell L, Friberger P, Gustavsson S, Karlsson G. Designing of peptide substrates. Haemostasis 1978; 7: 62-68
    PubMedGoogle Scholar
  • 29 Castillo MJ, Kurachi K, Nishino N, Ohkubo I, Powers JC. Reactivity of bovine blood coagulation factor IXa, factor Xa, and factor XIa toward fluorogenic peptides containing the activation sites sequences of bovine factor IX and factor X. Biochemistry 1983; 22: 1021-1029
    CrossrefPubMedGoogle Scholar
  • 30 Zimmerman M, Yurewicz E, Patel G. A new fluorogenic substrate for chymotrypsin. Anal Biochem 1976; 70: 258-262
    CrossrefPubMedGoogle Scholar
  • 31 Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epiderman growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C- activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264: 10351-10353
    PubMedGoogle Scholar
  • 32 Horie S, Ishi H, Hara H, Kazama M. Enhancement of thrombin-thrombomodulin-catalyzed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem J 1994; 301: 683-691
    CrossrefPubMedGoogle Scholar
  • 33 Miyata T, Funatsu A, Kato H. Chemical cross-linking of activated coagulation factor VH with soluble tissue factor calcium ions are not essential for full amidolytic activity of the factor VDa-tissue factor complex after complex formation. J Biochem 1995; 117: 836-844
    CrossrefPubMedGoogle Scholar
  • 34 Butenas S, Drungilaite V, Mann KG. Fluorogenic substrates for activated protein C: substrate structure-efficiency correlation. Anal Biochem 1995; 225: 231-241
    CrossrefPubMedGoogle Scholar
  • 35 Higgins DL, Mann KG. The interaction of bovine factor V and factor V-de- rived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-6508
    PubMedGoogle Scholar
  • 36 Lawson JH, Krishnaswamy S, Butenas S, Mann KG. Proteolytic activity of the extrinsic pathway. Methods Enzymol 1993; 222: 177-194
    PubMedGoogle Scholar
  • 37 Butenas S, Mann KG. Keinetics of human factor VH activation. Biochemistry 1996; 35: 1904-1910
    CrossrefPubMedGoogle Scholar
  • 38 Kolde HJ, Eberle R, Heber H, Heimburger N. New chromogenic substrates for thrombin with increased specificity. Thromb Haemost 1986; 56: 155-159
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Weinstein MJ, Doolittle RF. specificities of thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors. Biochim Biophys Acta 1972; 258: 577-590
    CrossrefPubMedGoogle Scholar
  • 40 Pierzchala PA, Dorn CP, Zimmerman M. A new fluorogenic substrate for plasmin. Biochem J 1979; 183: 555-559
    CrossrefPubMedGoogle Scholar
  • 41 Kato H, Adachi N, Ohno Y, Iwanaga S, Takada K, Sakakibara S. New fluorogenic peptide substrates for plasmin. J Biochem 1980; 88: 183-190
    PubMedGoogle Scholar
  • 42 Kiss I, Aurell L, Pozsgay M, Elodi P. Investigation on the substrate specificity of human plasmin using tripeptidyl-p-nitroanilide substrates. Biochem Biophys Res Commun 1985; 131: 928-934
    CrossrefPubMedGoogle Scholar
  • 43 Hamois-Pontoni M, Monsigny M, Mayer R. Hydrosoluble fluorogenic substrates for plasmin. Anal Biochem 1991; 193: 248-255
    CrossrefPubMedGoogle Scholar
  • 44 Butenas S, Kalafatis M, Mann KG. Analysis of tissue plasminogen activator specificity using peptidyl fluorogenic substrates. Biochemistry 1997; 36: 2123-2131
    CrossrefPubMedGoogle Scholar
  • 45 Lottenberg R, Hall JA, Blinder EP, Jackson CM. The action of thrombin on peptide p-nitroenilide substrates. Substrate selectivity and examination of hydrolysis under different reaction conditions. Biochim Biophys Acta 1983; 742: 539-557
    CrossrefPubMedGoogle Scholar
  • 46 Rezaie WR, Esmon CT. Convertion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. J Biol Chem 1993; 268: 19943-19948
    PubMedGoogle Scholar
  • 47 Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, Maraganore JM, Fenton II JW. Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. Biochemistry 1992; 31: 11689-11697
    CrossrefPubMedGoogle Scholar
  • 48 Le BonniecBF, Myles T, Johnson T, Knight CG, Tapparelli C, Stone SR. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Biochemistry 1996; 35: 7114-7122
    CrossrefPubMedGoogle Scholar
  • 49 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Wun T-C, Schleuning W-D, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
    PubMedGoogle Scholar
  • 51 von demBorne PA, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemostasis 1994; 72: 397-402
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Andreasen PA, Petersen LC, Dana K. Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator. Fibrinolysis 1991; 5: 207-215
    PubMedGoogle Scholar